| Not Yet Recruiting | Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutrop NCT06697262 | Centre Hospitalier Universitaire de la Réunion | N/A |
| Not Yet Recruiting | Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia NCT07277387 | Instituto de Investigación Biomédica de Salamanca | — |
| Not Yet Recruiting | Acupuncture as add-on to G-CSF for Febrile Neutropenia-related Hospitalization in Doxorubicin-treated Patients NCT06500715 | Shaare Zedek Medical Center | N/A |
| Recruiting | Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients. NCT07204522 | Shanxi Bethune Hospital | — |
| Recruiting | ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy NCT06657183 | Case Comprehensive Cancer Center | N/A |
| Not Yet Recruiting | Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia NCT06988826 | King Edward Medical University | Phase 4 |
| Recruiting | Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infe NCT06342115 | Beneficência Portuguesa de São Paulo | Phase 4 |
| Active Not Recruiting | Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study NCT06918587 | Kashiv BioSciences, LLC | Phase 1 |
| Withdrawn | Antimicrobial Revision in Persistent Febrile Neutropenia NCT05784844 | Wake Forest University Health Sciences | Phase 4 |
| Not Yet Recruiting | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications NCT06450821 | University of Leeds | N/A |
| Recruiting | Next-Generation-Sequencing Approach to Neutropenic Sepsis NCT05815628 | Boris Böll | — |
| Not Yet Recruiting | Early Neutropenic Fever De-escalation of Antibiotics Study NCT06278896 | Brigham and Women's Hospital | Phase 3 |
| Recruiting | Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Cl NCT06293677 | Centre Hospitalier Universitaire Vaudois | Phase 4 |
| Unknown | Lapelga vs Gastrofil NCT06116734 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 3 |
| Active Not Recruiting | Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patie NCT06787326 | Hospital Universitari de Bellvitge | — |
| Recruiting | Short Antibiotic Treatment in High Risk Febrile Neutropenia NCT05786495 | University Health Network, Toronto | N/A |
| Unknown | Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Thera NCT05576220 | IDION Inc. | N/A |
| Unknown | New Diagnostics in Neutropenia NCT05174546 | The University of Queensland | — |
| Unknown | Population Pharmacokinetics/Pharmacodynamics of Carbapenems in Febrile Neutropenia Patients NCT05665478 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Completed | Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN) NCT05584930 | University Hospital, Angers | N/A |
| Unknown | A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia NCT05311254 | Fundación para la Investigación Biosanitaria del Principado de Asturias | Phase 3 |
| Withdrawn | Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patie NCT04698057 | Poitiers University Hospital | Phase 3 |
| Unknown | Impact of Computerized Decision Support for ANTIBIOtic Prescription in Cancer Patients With Febrile NEutropeni NCT05206006 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia NCT04948463 | Murdoch Childrens Research Institute | Phase 4 |
| Unknown | mNGS Versus Blood Culture in FN NCT05149547 | Peking University People's Hospital | — |
| Completed | Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer. NCT04914702 | Insel Gruppe AG, University Hospital Bern | — |
| Unknown | Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology NCT04758442 | Ciusss de L'Est de l'Île de Montréal | N/A |
| Unknown | An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca NCT04662892 | Coherus Oncology, Inc. | — |
| Completed | Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile NCT04910698 | Poitiers University Hospital | — |
| Completed | Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy NCT04134429 | Insel Gruppe AG, University Hospital Bern | — |
| Unknown | Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic NCT04233996 | Hospital Universitari de Bellvitge | Phase 4 |
| Unknown | Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer NCT03618810 | Zhejiang Cancer Hospital | — |
| Unknown | G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients NCT03793205 | Lei Li | Phase 4 |
| Unknown | Long-acting G-CSF for Febrile Neutropenia NCT03740464 | Lei Li | Phase 3 |
| Completed | Ampholipad Real-World Data in Taiwan NCT03641131 | Taiwan Liposome Company | — |
| Completed | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents NCT03619252 | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Phase 4 |
| Unknown | iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patient NCT03364257 | Pathoquest | — |
| Terminated | Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic P NCT03342365 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia NCT03429387 | Peter MacCallum Cancer Centre, Australia | N/A |
| Completed | Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer NCT03104595 | Enzychem Lifesciences Corporation | Phase 1 / Phase 2 |
| Unknown | Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia NCT03449693 | Universidad Nacional Autonoma de Mexico | Phase 2 |
| Completed | Shared Health Information System for Febrile Neutropenia NCT03087227 | Marie-Helene METZGER | N/A |
| Active Not Recruiting | Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant NCT03078010 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) NCT02728596 | SWOG Cancer Research Network | N/A |
| Unknown | Profiling Neutrophil Counts in Patients on Chemotherapy NCT02806557 | University of Leeds | — |
| Completed | Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia NCT02856204 | Stanford University | — |
| Terminated | Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults Wi NCT02732327 | Forest Laboratories | Phase 2 |
| Terminated | Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophospham NCT02685111 | Asan Medical Center | Phase 2 |
| Completed | The Oral Cavity as a Source of Febrile Neutropenia NCT02702583 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Unknown | Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutrop NCT02536599 | Assiut University | — |
| Completed | Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients NCT03968328 | M.D. Anderson Cancer Center | — |
| Unknown | Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia NCT02463747 | Tel-Aviv Sourasky Medical Center | Phase 4 |
| Unknown | Cohort of Peripheral T Cell Lymphoma NCT02364466 | Korea Cancer Center Hospital | — |
| Completed | Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology P NCT02149329 | Amsterdam UMC, location VUmc | Phase 4 |
| Completed | Early Antibiotic Discontinuation in FUO NCT02906254 | University Hospital, Brest | — |
| Completed | Study of Danggui Buxue Decoction in Preventing Neutropenia NCT02005783 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Unknown | A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chem NCT01560195 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia NCT01581333 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 4 |
| Completed | A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy NCT01611051 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Withdrawn | Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia NCT01450241 | Rabin Medical Center | N/A |
| Unknown | Registry of Febrile Neutropenia and Invasive Fungal Infections NCT01684189 | Chang Gung Memorial Hospital | — |
| Completed | Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients Wi NCT01344681 | Yonsei University | Phase 2 |
| Terminated | Daptomycin Versus Placebo in Patients With Neutropenia and Fever NCT01216241 | University of Rochester | Phase 3 |
| Completed | A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemoth NCT02119715 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients NCT01401010 | Gary E. Stein, Pharm.D. | Phase 4 |
| Unknown | Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients NCT02544685 | S&D Pharma SK s.r.o. | Phase 2 |
| Completed | Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patien NCT01114165 | University Hospital Muenster | Phase 4 |
| Completed | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants Wit NCT01459653 | Sandoz | — |
| Completed | Procalcitonin Protocol to Shorten the Antibiotic Therapy in Febrile Neutropenia NCT00928291 | Federal University of Minas Gerais | N/A |
| Completed | Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical NCT00945555 | Pfizer | — |
| Completed | Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections NCT00709358 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia NCT00723073 | Brigham and Women's Hospital | — |
| Completed | Various G-CSF Regimens to Prevent Infection During Chemotherapy NCT00536081 | Academisch Ziekenhuis Maastricht | Phase 3 |
| Completed | Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia NCT00503854 | M.D. Anderson Cancer Center | — |
| Terminated | Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics NCT00421187 | Gilead Sciences | Phase 4 |
| Completed | Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases NCT00137787 | Center for Supporting Hematology-Oncology Trials | Phase 3 |
| Completed | Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patie NCT00454272 | Sanofi | Phase 4 |
| Completed | Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem C NCT00462878 | PETHEMA Foundation | — |
| Completed | Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection NCT00035425 | Pfizer | Phase 3 |